BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 31449833)

  • 21. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
    Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of donor lymphocyte infusions following mismatched stem cell transplantation.
    Or R; Hadar E; Bitan M; Resnick IB; Aker M; Ackerstein A; Samuel S; Tsirigotis P; Gesundheit B; Slavin S; Shapira MY
    Biol Blood Marrow Transplant; 2006 Dec; 12(12):1295-301. PubMed ID: 17162211
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of relapse after transplantation in acute leukemia: A comparative on second allogeneic hematopoietic cell transplantation and donor lymphocyte infusions.
    Ortí G; Sanz J; García-Cadenas I; Sánchez-Ortega I; Alonso L; Jiménez MJ; Sisinni L; Azqueta C; Salamero O; Badell I; Ferra C; de Heredia CD; Parody R; Sanz MA; Sierra J; Piñana JL; Querol S; Valcárcel D
    Exp Hematol; 2018 Jun; 62():24-32. PubMed ID: 29526774
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel treatment of severe combined immunodeficiency utilizing ex-vivo T-cell depleted haploidentical hematopoietic stem cell transplantation and CD45RA+ depleted donor lymphocyte infusions.
    Brodszki N; Turkiewicz D; Toporski J; Truedsson L; Dykes J
    Orphanet J Rare Dis; 2016 Jan; 11():5. PubMed ID: 26768987
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Similar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory or relapsed acute myeloid leukemia: A study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire.
    Decroocq J; Itzykson R; Vigouroux S; Michallet M; Yakoub-Agha I; Huynh A; Beckerich F; Suarez F; Chevallier P; Nguyen-Quoc S; Ledoux MP; Clement L; Hicheri Y; Guillerm G; Cornillon J; Contentin N; Carre M; Maillard N; Mercier M; Mohty M; Beguin Y; Bourhis JH; Charbonnier A; Dauriac C; Bay JO; Blaise D; Deconinck E; Jubert C; Raus N; Peffault de Latour R; Dhedin N
    Am J Hematol; 2018 Mar; 93(3):416-423. PubMed ID: 29226497
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparable outcome after haploidentical and HLA-matched allogeneic stem cell transplantation for high-risk acute myeloid leukemia following sequential conditioning-a matched pair analysis.
    Doppelhammer M; Fraccaroli A; Prevalsek D; Bücklein V; Häbe S; Schulz C; Hubmann M; Hausmann A; Claus R; Rank A; Schmid C; Tischer J
    Ann Hematol; 2019 Mar; 98(3):753-762. PubMed ID: 30617644
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: high remission rate among poor prognosis patients at the expense of graft-versus-host disease.
    de Lima M; Bonamino M; Vasconcelos Z; Colares M; Diamond H; Zalcberg I; Tavares R; Lerner D; Byington R; Bouzas L; da Matta J; Andrade C; Carvalho L; Pires V; Barone B; Maciel C; Tabak D
    Bone Marrow Transplant; 2001 Jan; 27(1):73-8. PubMed ID: 11244440
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NK cell recovery, chimerism, function, and recognition in recipients of haploidentical hematopoietic cell transplantation following nonmyeloablative conditioning using a humanized anti-CD2 mAb, Medi-507.
    Koenecke C; Shaffer J; Alexander SI; Preffer F; Dombkowski D; Saidman SL; Dey B; McAfee S; Spitzer TR; Sykes M
    Exp Hematol; 2003 Oct; 31(10):911-23. PubMed ID: 14550807
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect.
    Dodero A; Spina F; Narni F; Patriarca F; Cavattoni I; Benedetti F; Ciceri F; Baronciani D; Scimè R; Pogliani E; Rambaldi A; Bonifazi F; Dalto S; Bruno B; Corradini P
    Leukemia; 2012 Mar; 26(3):520-6. PubMed ID: 21904377
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Donor lymphocyte infusion for prevention of relapse after unmanipulated haploidentical PBSCT for very high-risk hematologic malignancies.
    Gao XN; Lin J; Wang SH; Huang WR; Li F; Li HH; Chen J; Wang LJ; Gao CJ; Yu L; Liu DH
    Ann Hematol; 2019 Jan; 98(1):185-193. PubMed ID: 30143831
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low-dose methotrexate may preserve a stronger antileukemic effect than that of cyclosporine after modified donor lymphocyte infusion in unmanipulated haploidentical HSCT.
    Yan CH; Xu LP; Liu DH; Chen H; Wang Y; Wang JZ; Wang FR; Han W; Liu KY; Huang XJ
    Clin Transplant; 2015 Jul; 29(7):594-605. PubMed ID: 25969866
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
    Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Donor Lymphocyte Infusion-Mediated Graft-versus-Host Responses in a Preclinical Swine Model of Haploidentical Hematopoietic Cell Transplantation.
    Duran-Struuck R; Matar AJ; Crepeau RL; Teague AGS; Horner BM; Pathiraja V; Spitzer TR; Fishman JA; Bronson RT; Sachs DH; Huang CA
    Biol Blood Marrow Transplant; 2016 Nov; 22(11):1953-1960. PubMed ID: 27543159
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemotherapy followed by modified donor lymphocyte infusion as a treatment for relapsed acute leukemia after haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: superior outcomes compared with chemotherapy alone and an analysis of prognostic factors.
    Yan CH; Wang JZ; Liu DH; Xu LP; Chen H; Liu KY; Huang XJ
    Eur J Haematol; 2013 Oct; 91(4):304-14. PubMed ID: 23837640
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis.
    Ghosh N; Karmali R; Rocha V; Ahn KW; DiGilio A; Hari PN; Bachanova V; Bacher U; Dahi P; de Lima M; D'Souza A; Fenske TS; Ganguly S; Kharfan-Dabaja MA; Prestidge TD; Savani BN; Smith SM; Sureda AM; Waller EK; Jaglowski S; Herrera AF; Armand P; Salit RB; Wagner-Johnston ND; Fuchs E; Bolaños-Meade J; Hamadani M
    J Clin Oncol; 2016 Sep; 34(26):3141-9. PubMed ID: 27269951
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the safety and efficacy of prophylactic donor lymphocyte infusion after haploidentical versus matched-sibling PBSCT in very high-risk acute myeloid leukemia.
    Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
    Ann Hematol; 2019 May; 98(5):1267-1277. PubMed ID: 30747249
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incorporation of high-dose
    Lee JW; Kang ES; Sung KW; Yi E; Lee SH; Yoo KH; Koo HH
    Pediatr Blood Cancer; 2017 Jun; 64(6):. PubMed ID: 28012219
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective Series.
    Pawarode A; Mineishi S; Reddy P; Braun TM; Khaled YA; Choi SW; Magenau JM; Harris AC; Connelly JA; Kitko CL; Parkin BL; Goldstein SC; Yanik GA; Levine JE; Ferrara JL; Couriel DR
    Biol Blood Marrow Transplant; 2016 Jan; 22(1):54-60. PubMed ID: 26211984
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies.
    Branson K; Chopra R; Kottaridis PD; McQuaker G; Parker A; Schey S; Chakraverty RK; Craddock C; Milligan DW; Pettengell R; Marsh JC; Linch DC; Goldstone AH; Williams CD; Mackinnon S
    J Clin Oncol; 2002 Oct; 20(19):4022-31. PubMed ID: 12351600
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of graft-versus-leukemia to prevent relapse after partially lymphocyte-depleted allogeneic bone marrow transplantation by pre-emptive donor leukocyte infusions.
    Schaap N; Schattenberg A; Bär B; Preijers F; van de Wiel van Kemenade E; de Witte T
    Leukemia; 2001 Sep; 15(9):1339-46. PubMed ID: 11516094
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.